Challenges in developing Geroscience trials
-
Published:2023-08-19
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Rolland YvesORCID, Sierra Felipe, Ferrucci LuigiORCID, Barzilai Nir, De Cabo Rafael, Mannick Joan, Oliva Anthony, Evans William, Angioni Davide, De Souto Barreto Philipe, Raffin Jeremy, Vellas Bruno, Kirkland James L.ORCID, Andrieu Sandrine, Bacqueville Daniel, Bischoff-Ferrari Heike, Blivet Guillaume, Cash Timothy, Cuervo Ana-Maria, Davezac Noelie, Dimet-Wiley Andrea, Fleming Alexander, Gérard Friedlander, Gonzales Mitzi, Guyonnet Sophie, Hare Joshua, Hendrix Suzanne, Jorgensen Christian, Kaeberlein Matt, Khan Mehmood, Kritchevsky Stephen, Labokha Aksana, Lairez Olivier, Lederman Stephanie, Mariani Jean, Middleton Lefkos, Newman John, Parini Angelo, Peschin Susan, Prunotto Marco, Sagol Sami, Tomlinson Suzanne, Terstappen Georg, Touchon Jacques, Tourette Cendrine, Van Maanen Rob, Verdin Eric, Watowich Stan, Zhang Lei, Zhavoronkov Alex,
Abstract
AbstractGeroscience is becoming a major hope for preventing age-related diseases and loss of function by targeting biological mechanisms of aging. This unprecedented paradigm shift requires optimizing the design of future clinical studies related to aging in humans. Researchers will face a number of challenges, including ideal populations to study, which lifestyle and Gerotherapeutic interventions to test initially, selecting key primary and secondary outcomes of such clinical trials, and which age-related biomarkers are most valuable for both selecting interventions and predicting or monitoring clinical responses (“Gerodiagnostics”). This article reports the main results of a Task Force of experts in Geroscience.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference101 articles.
1. Franceschi, C. et al. The continuum of aging and age-related diseases: common mechanisms but different rates. Front Med. 5, 61 (2018). 2. Harper, S. Economic and social implications of aging societies. Science 346, 587–591 (2014). 3. Seals, D. R., Justice, J. N. & LaRocca, T. J. Physiological geroscience: targeting function to increase healthspan and achieve optimal longevity. J. Physiol. (Lond.). 594, 2001–2024 (2016). 4. Kulkarni, A. S. et al. Geroscience-guided repurposing of FDA-approved drugs to target aging: a proposed process and prioritization. Aging Cell. 21, e13596 (2022). 5. Wyles, S. P., Tchkonia, T. & Kirkland, J. L. Targeting cellular senescence for age-related diseases: path to clinical translation. Plast. Reconstr. Surg. 150, 20S–26S (2022).
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|